JNJ logo

JNJJohnson & Johnson

$239.10
$0.61
(0.26%)
Pre-Market
Updated: 05:29 AM EDT·Prev Close $238.49
EarningsJul 15
Mkt Cap$570.51B
Vol4,059.00
65

Bullish Sentiment

How do you feel about JNJ?

News
all
press releases
IMAAVY (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
IMAAVY (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies IMAAVY (nipocalimab-aahu) demonstrates durable hemoglobin response and...
PR Newswire
News Placeholder
More News
News Placeholder
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
JNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.
Zacks
News Placeholder
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
Zacks
News Placeholder
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.
Zacks
News Placeholder
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Zacks
News Placeholder
Johnson & Johnson To Acquire Firefly Bio To Expand Oncology Pipeline
(RTTNews) - Johnson & Johnson (JNJ) on Monday announced a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company for $1 billion in cash...
Nasdaq News: Markets
News Placeholder
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink DAC platform for KRAS-driven tumors...
Business Wire
News Placeholder
Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock
Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock...
Yahoo! Finance: News
News Placeholder
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations...
Yahoo! Finance: News
News Placeholder
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
Zacks
<
1
2
...
>

Advertisement|Remove ads.